Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

NKX3.1 Monoclonal Antibody (OTI1C11), TrueMAB™, OriGene
SDP

Catalog No. 501680544
Encompass_Preferred
Change view
Click to view available options
Quantity:
100 μL
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
50-168-0544 100 μL
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. 50-168-0544 Supplier OriGene Supplier No. TA805087
Only null left
Add to Cart
Add to Cart

Mouse Monoclonal Antibody

The homeodomain-containing transcription factor NKX3-1 is a putative prostate tumor suppressor that is expressed in a largely prostate-specific and androgen-regulated manner. Loss of NKX3-1 protein expression is a common finding in human prostate carcinomas and prostatic intraepithelial neoplasia.

Specifications

Antigen NKX3.1
Applications Western Blot
Classification Monoclonal
Clone OTI1C11
Concentration 1 mg/mL
Conjugate Unconjugated
Formulation PBS with 1% BSA, 50% glycerol and 0.02% sodium azide
Gene NKX3-1
Gene Accession No. Q99801
Gene Alias BAPX2, NKX3, NKX3.1, NKX3A
Gene Symbols NKX3-1
Host Species Mouse
Immunogen Full length human recombit protein of human NKX3-1 produced in E.coli.
Purification Method Affinity Chromatography
Quantity 100 μL
Regulatory Status RUO
Primary or Secondary Primary
Gene ID (Entrez) 4824
Target Species Human
Content And Storage -20° C, Avoid Freeze/Thaw Cycles
Product Type Antibody
Form Liquid
Isotype IgG1
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.